New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2012
06:10 EDTBRK.A, XOM, LNVGY, MU, CVX, AAPL, RDS.A, BPOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Wireless carriers are beginning to change the terms of smartphone deals that have mostly benefited phone makers like Apple (AAPL), in a move that could leave consumers paying more for devices like the iPhone, the Wall Street Journal reports...Lenovo Group (LNVGY) said it plans to spend about $800M on a new base to house the development, production and sale of mobile products as it attempts to expand beyond its core PC business, the Wall Street Journal reports...BLOOMBERG: Oil dropped about 3.2% to the lowest level in more than four months after European elections increased speculation that austerity efforts will be derailed and weak jobs data underscored concern the U.S. economy may falter, Bloomberg reports...Individual investors are putting more money into bank-loan funds, adding risk in a search for higher yields and a hedge against inflation as the Fed says it will keep interest rates at near record lows, Bloomberg reports...REUTERS: Micron Technology (MU) won the right to negotiate exclusively to buy Elpida Memory after offering over $2.5B for the failed Japanese chipmaker, sources say, Reuters reports...Warren Buffett said he recently considered an unidentified $22B acquisition for his Berkshire Hathaway (BRK.A), adding that if Berkshire didn't make a major deal this year, it could look at one over $30B next year, Reuters reports.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use